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(57) ABSTRACT
A nonradioactive glass in particulate form adapted for 
radiation therapy in a mammal comprise a biodegradable 
rare earth-lithium borate glass material of a specified com­
position which, upon being subjected to an effective amount 
of neutron irradiation, will produce a beta or gamma emit­
ting radioisotope, the radioisotope being distributed 
throughout the glass material, the glass upon being intro­
duced into a body fluid for radiation therapy being adapted 
to react therewith causing the radioisotope to form an 
insoluble compound on the surface of the glass material 
which is retained in the glass material and thereby prevented 
from escaping from the treatment site. Radioactive glasses 
and methods for carrying out radiation therapy with such 
radioactive glasses are also disclosed.
11 Claims, 7 Drawing Sheets
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BIODEGRADABLE GLASS COMPOSITIONS 
AND METHODS FOR RADIATION 
THERAPY
BACKGROUND OF THE INVENTION
This invention relates to radiation therapy such as radia­
tion synovectomy of arthritic joints and biodegradable glass 
compositions in particulate form for use in radiation therapy.
Currently, no material for the in vivo delivery of thera­
peutic doses of beta radiation have been approved for use in 
the United States for irradiation of diseased organs in the 
body, e.g. malignant tumors and the inflamed synovium of 
arthritic joints. Materials that have been investigated previ­
ously for in vivo radiotherapy can be classified as bio-inert 
(non-degradable) glasses (e.g. Ehrhardt et al. Nuc. Med. 
Biol., 14 [3] (1987); Ehrhardt et al., Soc. of Nuc. Med., 39th 
Annual Meeting, June 9-12 (1992); Day et al., Advanced 
Series in Ceramics—Vol. 1, p. 305-317, World Scientific 
(1994); Hyatt et al., J. Am. Ceram. Soc., 70 [10] (1987); and 
Erbe et al., J. Biomed. Mat. Res., 27, 1301-1308 (1993)) or 
non-glasses (e.g. Ansell, Ann. Rheum. Dis., 6 Supp. 1-2 
(1993); Ingrand, Ann. Rheum. Dis., 6 Supp. 3-9 (1973); 
Boerbooms et al., Eur. J. Nuc. Med., 10 (1985); Spooren et 
al., Eur. J. Nuc. Med., 10 (1985); and Neves et al., Appl. 
Rad. Isat., 38 [9] (1987)). All of these materials can be 
administered to the patient by injection in a similar fashion.
Bio-inert radiotherapy glass particulates have already 
demonstrated the effectiveness of glass materials for safely 
delivering large localized does of therapeutic beta radiation. 
However, such glasses are limited to therapies where the 
glass can remain in the body indefinitely. Radiation syn­
ovectomy of diseased joints is one example of an application 
where the eventual removal (clearance) of the radiopharma­
ceutical may be desired. This creates the need for a biode­
gradable material.
Non-glass materials that have been proposed for use as 
radiopharmaceuticals include radiocolloids and ceramic, 
polymer or protein particulates that have a radioactive 
isotope attached (bonded) to their surface. Several of these 
non-glass materials can be cleared from in vivo treatment 
sites such as a rheumatoid arthritic joint. Each has 
shortcomings, however, that limits their usefulness and 
safety during preparation and use. These shortcomings 
include: (1) release of excessive or potentially dangerous 
amounts of radiation outside the treatment site. This 
unwanted release has occurred due to the physical escape of 
the intact radioactive materials, the disintegration of the 
materials into smaller particles or ionic species while still 
radioactive, or the “debonding” of the radioisotope from the 
surface of a particle when in contact with body fluids; (2) the 
radiation dose is limited to amounts smaller than desired for 
certain applications; (3) complex preparation procedures 
that include handling radioactive substances during fabrica­
tion; and (4) use of radioisotopes with a short half life, which 
means that the material must be used quickly. This limits the 
time available for distributing (mailing) the radiopharma­
ceutical and causes other inconveniences.
Beta-emitting radionuclides are considered the most use­
ful for radiotherapeutic applications because of the moderate 
linear energy transfer (LET) of the ionizing particle 
(electron) and its intermediate range (typically several mil­
limeters in tissue). Gamma rays deliver dosage at lower 
levels over much greater distances. Alpha particles represent 
the other extreme; they deliver very high LET dosage, but 
have an extremely limited range and must, therefore, be in 
intimate contact with the cells of the tissue to be treated. In
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addition, alpha emitters are generally heavy metals, which 
limits the possible chemistry and presents undue hazards 
from leakage of radionuclide from the area to be treated.
It is fortuitous that beta emitters, the most useful radio- 
therapeutic radionuclides, are also the ones most copiously 
produced by neutron capture in nuclear reactors, the most 
powerful sources of radioisotopes. Reactor-produced iso­
topes number in the thousands, giving researchers a wide 
choice of isotopes of various half-lives, beta energies, 
gamma emissions, and chemical properties. Gamma 
emissions, while not as useful as beta emissions, play an 
important role in that they permit the distribution of radio­
isotope in the body to be observed using an Anger gamma 
ray camera or single photon computed tomography (SPECT) 
instrument. This permits direct observation and, to some 
extent, quantification of radionuclide leakage from an organ 
or a joint and also provides positive verification of the 
potency of joint injection and distribution of the radionu­
clide in the research animal.
With respect to radiation synovectomy of arthritic joints, 
treatment of the different depths of diseased synovium in 
joints of disparate size, such as the finger joints and the knee, 
requires isotopes of different average beta range. It is 
important to achieve a “kill” of sufficient depth to be 
efficacious without causing significant necrosis of overlying 
normal tissues.
Rare earth containing glass microspheres have been con­
sidered for radiation synovectomy treatment of rheumatoid 
arthritic joints. The radioactive glass microspheres could be 
injected directly into the synovial sac and deliver enough 
radiation ( = 10,000 rads (cGy)) to destroy the inflamed 
lining of the diseased synovial membrane. Radiocolloid 
particulates, e.g. 90Y or 198Au salts, are presently used in 
Europe for radiation synovectomy (e.g. Houle et al., Radi­
ology 172 [3] 1989); Russel et al., Endocurietherapy/ 
Hyperthermia Oncology, 4 [7] 171-186 (1988); Sledge et 
al., Arth. Rheum. 29 [2] 153-159 (1986); Davis et al., J. 
Nucl. Med., 30 [6] 1047-1055 (1989); Hall, Orthop. Clin. 
North Am., 6, 675-684 (1975); and Taylor et al., Ann. 
Rheum. Dis., 31, 159-161 (1972)), but have not been 
approved for use in the United States because of unaccept­
able amounts of radiation leakage during their use. The 
radiocolloids are known to easily escape the synovium due 
to their sub-micron size, and in certain instances 25% of the 
targeted radiation has been deposited in healthy tissue out­
side the joint. Glass microspheres for radiotherapy are much 
larger (>1 fim in diameter) than the radiocolloids and have 
the additional advantage of a carefully controlled size within 
a few microns.
U.S. Pat. No. 5,011,797 dated Apr. 30, 1991 discloses 
radioactive microspheres for radiation synovectomy of 
arthritic joints which comprise a biodegradable glass mate­
rial and a beta radiation emitting radioisotope chemically 
dissolved in and distributed substantially uniformly through­
out the glass material. The biodegradable glass material may 
be lithium silicate, lithium aluminosilicate, lithium 
a l u m i n o b o r a t e ,  l i t h iu m  g e r m a n a t e ,  l i t h iu m  
aluminogermanate,  potassium  silicate, potassium 
aluminosilicate, potassium aluminoborate, potassium ger­
manate or potassium aluminogermanate and the beta radia­
tion emitting radioisotope may be samarium-153, holmium- 
166, erbium-169, dysprosium-165, rhenium-186, rhenium- 
188 or yttrium-90. The patent also discloses non- 
biodegradable glass materials such as magnesium 
aluminosilicate and aluminosilicate glass materials which 
contain a beta radiation emitting radioisotope.
There is a continuing need for improved glass materials 

















SUMMARY OF THE INVENTION
Among the several objects of the invention may be noted 
the provision of novel biodegradable rare earth-lithium 
borate glass materials for use in radiation therapy; the 
provision of such glass materials containing beta or gamma 
emitting radioisotopes; the provision of such glass materials 
in the form of microspheres; the provision of such biode­
gradable glass materials which upon being introduced into a 
body fluid for radiation therapy are adapted to react there­
with causing the radioisotope contained therein to react with 
the body fluid causing the radioisotope to form an insoluble 
compound on the surface of the glass material which is 
retained on the glass material and thereby prevented from 
escaping from the treatment site; and the provision of 
methods for carrying out radiation therapy such as radiation 
synovectomy of arthritic joints. Other objects and features 
will be in part apparent and in part pointed out hereinafter.
Briefly, the present invention is directed to novel radio­
active glass in particulate form for radiation therapy in a 
mammal comprising a biodegradable glass material having 
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wherein RE is a neutron activatable rare earth which emits 
a therapeutic intensity of beta or gamma radiation, the 
radioisotope being distributed throughout the glass material, 
x is the mole percent of RE20 3 and ranges between approxi­
mately 0.5 and 5 and y is the mole percent of Li20 , MgO or 
A120 3 and the balance is a lithium borate material glass. The 
lithium borate glass is substantially free of lithium-6 and 
boron-10 and the glass upon being introduced into a body 
fluid for radiation therapy is adapted to react therewith 
causing the radioisotope to form an insoluble compound on 
the surface of the glass material which is retained in the glass 
material and thereby prevented from escaping from the 
treatment site.
Another aspect of the invention resides in the provision of 
novel nonradioactive glass in particulate form which, upon 
being subjected to an effective amount of neutron 
irradiation, will produce a beta or gamma emitting radio­
isotope thereby rendering the glass material suitable for use 
for radiation therapy while avoiding the handling of radio­
active elements during initial production of the glass mate­
rial.
Still another aspect of the invention lies in the provision 
of novel methods for carrying out radiation therapy such as 
radiation synovectomy of arthritic joints utilizing the novel 
radioactive glass material of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic showing the formation of a corro­
sion (reaction) layer on the surface of rare earth-lithium 
borate glass microspheres as a result of non-uniform disso­
lution;
FIG. 2 is a representative SEM photomicrograph of 
dysprosium-lithium-aluminoborate (DyLAB) glass micro­
spheres prepared by flame spheroidization. White bar is 10 
fim;
FIG. 3 shows representative SEM photomicrographs of 
(A) DyLAB-5, (B) DyLAB-10, (C)DyLAB-15, and (D)
3
DyLAB-20 glass microspheres after immersion in PBS 
solution (pH 7.4) at 37° C. for 24 hours. Shrinkage and 
cracking on the surface of the DyLAB glass microspheres in 
both (A) and (B) appeared after the spheres were removed 
from solution. Notice the smooth surface texture of both the 
glass and corrosion layer. White bar is 10 fim;
FIG. 4 shows representative photomicrographs (200x) of 
the surface of a (A) DyLAB-5, (B) DyLAB-10, (C) DyLAB- 
15, and (D) DyLAB-20 glass plate after immersion in PBS 
solution (pH 7.4) for 11 days at 37° C. Evidence of a 
corrosion (reaction) layer is seen (as cracks) in (A) and (B) 
but not in (C) or (D). The edge of the DyLAB glass plate is 
shown near the top of the photo in (C) and (D).
FIG. 5 shows chronological video images (220x) of a 
group of DyLAB-10 glass microspheres after immersion in 
PBS solution (pH 7.4) at 22° C. for the time (in hours) 
shown in the upper left corner. The layer forming on the 
outer surface of the glass microspheres becomes detectable 
after about 26 hours and becomes progressively thicker with 
time. The external diameter of the microspheres remains 
nearly constant while the diameter of the unreacted core 
becomes progressively smaller. The average diameter of the 
microspheres was 28 fim;
FIG. 6 shows photomicrographs (A) 120x and (B) 480x 
of DyLAB-10 glass microspheres (20-25 fim in diameter) 
imbedded in a synovial membrane two weeks after injection 
into the healthy stifle joint of a rat. The arrows in (A) point 
to (1) the glass microspheres imbedded in the synovial 
membrane; (2) the articular cartilage and (3) bone. Degra­
dation of the glass microspheres is indicated in (B); a 
corrosion layer (1) surrounds a glass core (2); and
FIG. 7 is a photomicrograph (480x) of (1) two DyLAB-10 
glass microspheres engulfed by (2) macrophages (elliptical 
shape) two weeks after injection into the healthy stifle joint 
of a rat. Degradation of the microspheres is indicated by 
discoloration at the surface and by a change in shape from 
spherical to irregular.
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS
In accordance with the present invention, it has now been 
found that a certain class of novel radioactive glass materials 
in particulate form may be used for the in vivo irradiation of 
diseased organs in the body, e.g. malignant tumors and the 
inflamed synovium of arthritic joints. The glass materials 
may be in the form of microspheres which, upon being 
introduced into a body fluid for radiation therapy are adapted 
to have the beta or gamma emitting radioisotope contained 
therein react with the body fluid causing the radioisotope to 
form an insoluble compound on the surface of the glass 
material which is retained in the glass material and thereby 
prevented from escaping from the treatment site to other 
sites in the body. The radioactive glass materials of the 
invention are prepared from novel nonradioactive glass 
materials which may be manufactured, sized, and processed 
in other ways before radioactivity is induced providing the 
advantage of working only with nonradioactive materials 
during initial production of the glass materials.
In a first embodiment of the invention, the novel radio­
active materials in particulate form (e.g. microspheres) are 
comprised of a biodegradable glass material having one of 
the following compositions:
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wherein RE is a neutron activatable rare earth radioisotope 
which emits a therapeutic intensity of beta or gamma 
radiation and is distributed throughout the glass material, x 
is the mole percent of RE20 3 and ranges between approxi­
mately 0.5 and 5, y is the mole percent of Li20 , MgO or 
A120 3 and the balance is a lithium borate glass material.
The lithium borate glass material is substantially free of 
lithium-6 and boron-10. Lithium-6 is a 7.4% naturally 
abundant isotope which forms tritium when naturally occur­
ring lithium compounds are bombarded with neutrons. Tri­
tium is a beta emitter with a half life of 12.5 years. 
Accordingly, compounds which contain just lithium-7 
should be used since no radioactive isotopes are formed 
when lithium-7 is bombarded with neutrons. Boron-10 is an 
isotope with a large thermal cross section, 3837 barns, which 
would be detrimental in a glass material of the present 
invention because the glass might absorb so many neutrons 
as to prevent other portions of the glass from becoming 
radioactive. This problem can be avoided by using com­
pounds which contain only boron-11 that has a much smaller 
thermal cross section, about 0.005 barns.
Any neutron activatable rare earth radioisotope which 
emits a therapeutic intensity of beta or gamma radiation may 
be used in the practice of the invention as a component of the 
above-noted glass material compositions. As used herein, 
the term neutron activatable rare earth radioisotope includes 
yttrium-90. Illustrative beta or gamma emitting radioiso­
topes include dysprosium-165, holmium-166, yttrium-90, 
rhenium-186, rhenium-188 and samarium-153. These beta 
or gamma emitting radioisotopes are particularly suitable for 
use in the present invention. Samarium-153 (46.3 hr. half- 
life) and holmium-166 (26.8 hr. half-life) can be readily 
dissolved in the above-noted glass compositions, have good 
activation properties in a nuclear reactor, possess imageable 
gamma rays, exhibit low toxicity and have half-lives long 
enough for distribution of the radioactive glass materials 
containing them.
Holmium-166 is produced by neutron capture on 100% 
abundant, stable holmium-165 with thermal neutron and 
resonance neutron cross sections of 61.2 and 67.0 barns, 
respectively. It decays with a 26.83 hour half-life by emis­
sion of 1.855 MeV (51%) and 1.776 MeV (48%) maximum 
energy beta particles with a maximum range of about 8.0 
mm and an average range of about 2 mm. Since dysprosium- 
165 emits a beta particle of slightly lower maximum energy 
(1.31 MeV) and has proven efficacious in human knee 
radiation synovectomies, it appears that holmium-166 has 
sufficient penetration for this application. Ho-166 has suf­
ficient penetration for this application. Ho-166 also emits an 
80.5 Kev gamma ray in 6.2% abundance and thus is image- 
able by conventional techniques.
Samarium-153 is produced by neutron capture of natural 
or isotopically enriched samarium-152 with thermal and 
resonance neutron cross sections of 210 and 3,020 barns, 
respectively, it decays by beta emissions of 0.810 MeV 
(20%) 0.710 MeV (49%) and 0.640 MeV (30%) maximum 
energies with concomitant ranges of about 2.3 mm maxi­
mum and 0.8 mm average distance, respectively. Sm-153 
has a physical half-life of 46.27 hours and produces a highly 
imageable 103 KeV gamma ray with an abundance of 
29.8%, decaying to stable Eu-153.
Samarium-153 and holmium-166 are both chemically 
compatible and capable of being incorporated into the 
above-noted glass compositions in which no other signifi­
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cant radioactivities induced by neutron bombardment will be 
present after about one day of decay. Dysprosium-165, 
yttrium-90, rhenium-186 and rhenium-188 and other beta or 
gamma emitting radioisotopes may also be used as the 
radioisotope in the practice of the invention.
Illustrative of the biodegradable lithium borate glass 
materials within the above-noted compositions may be men­
tioned the following:
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Dy20 3 1.7 mole %
Li20 24.6 mole %
B20 3 73.7 mole %
100.0 mole %
Dy20 3 5 mole %
Li20 16 mole %
a i2o 3 5 mole %
b 2o 3 66 mole %
s io 2 5 mole %
MgO 3 mole %
100 mole %
Dy20 3 5 mole %
Li20 15 mole %
a i2o 3 10 mole %
b 2o 3 62 mole %
S i0 2 5 mole %
MgO 3 mole %
100 mole %
Ho20 3 2 mole %
Li20 15 mole %
a i2o 3 15 mole %
b 2o 3 60 mole %
S i0 2 5 mole %
MgO 3 mole %
100 mole %
It will be understood that other radioisotope-containing 
lithium borate glass materials within the above-noted com­
positions may also be used in the practice of the invention.
As previously indicated, the biodegradable rare earth- 
lithium borate glass materials of the invention corrode, react 
or biodegrade in the body at controlled rates determined by 
the specific glass composition. This biodegradation occurs 
in such a way that none of the beta or gamma emitting 
radioisotope contained in the glass escapes from the treat­
ment site. Preferably, the glass materials are formed into 
microspheres of nearly any desired size, preferably micro­
spheres having a diameter less than 100 microns and, more 
preferably, having a diameter between approximately 1 and 
40 microns.
After administration to the treatment site for radiation 
therapy as by injection or other suitable conventional means 
known to the art, the radioactive rare earth element either 
reacts with another constituent in the glass or with a body 
fluid to form an insoluble compound on the surface of the 
glass material, which insoluble compound may eventually 
form throughout the glass material and be retained on the 
glass material and is thereby prevented from escaping from 
the treatment site. Referring to FIG. 1, there is shown a 
simplified model for the degradation or corrosion charac­
teristics of dysprosium-165, holmium-166 or other rare earth 
lithium borate glass microspheres of the invention as 
employed for in vivo radiation therapy. FIG. 1 shows the 
presence of a corrosion or reaction layer on the surface of the 
glass microsphere due to the dissolution of the B20 3, Li20, 
MgO and, to a lesser extent, A120 3 and Si02. The insoluble 
compound formed and retained on the glass material to 















example, a rare earth oxide, rare earth, hydroxide or rare 
earth phosphate. Some of the probable products of dissolu­
tion and undissolved Dy20 3 or Ho20 3, A120 3 and Si02 are 
shown in FIG. 1. The diffusion of P, K and Na ions from 
body fluids into the corrosion or reaction layer of the glass 
microsphere is also indicated in FIG. 1. The undissolved 
oxides in the corrosion layer may become partially hydrated.
As shown by the experimental work set forth hereinafter, 
no measurable amount of radioactivity was released from 
neutron activated DyLAB glass microspheres after being 
immersed in deionized water at 37° C. for 11 hours. The lack 
of release of dysprosium-165 from the radioactive DyLAB 
microspheres was confirmed by similar measurements using 
non-radioactive microspheres.
Degradation of the rare earth lithium borate glass mate­
rials of the invention was observed during in vitro testing as 
set forth hereinafter. The DyLAB glass microspheres shown 
in FIG. 5 demonstrate the unique degradation characteristics 
of the glass materials of the invention. Although none of the 
radioactive component is released, the glass material began 
to react within 24 hours in a PBS solution at 37° C. This is 
shown in FIG. 5 as the formation of a rare earth rich reaction 
layer on the DyLAB microspheres and indicates that the 
glasses will be degradable in the body.
The degradation rate of the glass materials of the inven­
tion can be easily controlled from approximately 10-6 to 
10-10 g/cm2/min. by adjusting the glass composition. Thus, 
the rare earth-lithium borate glasses of the invention can 
safely accommodate a variety of useful radioisotopes (beta 
or gamma emitters) whose half-life ranges from as little as 
2 hours to as much as 7 days. This factor greatly enhances 
the versatility of the glass materials of the invention for in 
vivo radiotherapy.
The results of the in vitro studies and in vivo testing of the 
glass materials of the invention set forth hereinafter are in 
good agreement. A reaction or corrosion layer, similar to that 
shown in FIG. 5, also formed on the glass microspheres that 
were injected into the healthy stifle joints of a rat (see FIGS. 
6 and 7). There was no detected difference between the 
dissolution characteristics of the glass microspheres injected 
into the joints of a rat and those immersed in simulated body 
fluids.
The glass materials of the present invention, in the form 
of microspheres, may be prepared from a homogeneous 
mixture of powders (i.e. the batch) that is melted to form the 
desired glass composition. The exact chemical compounds 
or raw materials used for the batch is not critical so long as 
they provide the necessary oxides in the correct proportion 
for the melt composition being prepared. The mole and 
weight percent of illustrative components of glass materials 
of the invention are set forth in Tables II through V here­
inafter. The purity of each raw material is typically greater 
than 99.9%. After either dry or wet mixing of the powders 
to achieve a homogeneous mixture, the mixture may be 
placed in a platinum or platinum/rhodium alloy crucible for 
melting in an electric furnace. The raw materials must not 
contain impurities that become radioactive from neutron 
irradiation.
After the crucible is removed from the furnace, the melt 
is then cast into a bar or patty on a stainless steel plate. For 
glass microsphere formation, the glasses are crushed with a 
mortar and pestle to obtain glass powders. The powders are 
then fed to a propane/air flame where each particle is melted 
and spheroidized due to surface tension. The spherical 
particles are cooled to solid glass microspheres and col­
lected. The glass materials of the invention can be readily 
made into microspheres of nearly any desired size, prefer­
ably having a diameter of less than approximately 100 
microns and, more preferably, a diameter between approxi­
mately 1 and 40 microns.
The glass materials of the invention, in particulate form 
such as microspheres, may be activated by being subjected
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to an effective amount of neutron irradiation which will 
produce a beta or gamma radiation emitting radioisotope 
such as, for example, dysprosium-165, holmium-166, 
yttrium-90, rhenium-186, rhenium-188 or samarium-153, 
the amount depending upon the particular isotope of such 
elements that has been chemically dissolved and uniformly 
distributed throughout the glass materials. Since the glass 
materials are made radioactive after they are fabricated, all 
glass melting and fabrication into microspheres, for 
example, advantageously involves only non-radioactive 
materials.
As indicated, the radioactive glass compositions of the 
present invention prepared as described may be adminis­
tered for the in vivo irradiation of diseased organs such as 
malignant tumors and the inflamed synovium of arthritic 
joints. These novel glass compositions in the form of glass 
microspheres, for example, may be administered by intra- 
articular injection or by other suitable means of administra­
tion. When employed for radiation synovectomy of arthritic 
joints, for example, the glass compositions are introduced 
into synovial fluid, become distributed reasonably uniformly 
in the synovial membrane to a depth of about 50 to 100 
microns, and emit beta radiation to substantially fully irra­
diate the thickness of the membrane without significant 
dosage to more distant joint structures with the radioisotope 
being retained in the glass material to prevent migration 
from the treatment site.
The novel glass compositions of the present invention 
offer the significant advantages of in situ degradability, 
significantly decreased potential for radiation escaping from 
the treatment site, and ease of preparation. Such glass 
compositions also enable the use of larger radiation doses 
than can currently be delivered by non-glass radiotherapy 
materials, use relatively inexpensive materials and can be 
delivered to essentially any site in the body by simple 
injection. The nonradioactive glass compositions of the 
invention also possess an indefinite shelf life.




The rare earth-lithium borate glasses listed in Table I, 
containing either Dy20 3, Ho20 3, Y20 3 or Sm20 3, were 
prepared by melting a homogeneous mixture of analytical 
grade powders of the rare earth oxides in a platinum or 
platinum/rhodium alloy crucible in an electric furnace. All 
bath materials used in glass preparation were oxides with the 
exception of H3B 03 and Li2C 03.
TABLE I
8
Mole Percent Composition of Rare Earth-Lithium- 









xDy20 3.(100 -  x)LiB30 5 




xDy2O 3.yMgO.(100 -  x -  y)LiB30 5 
























Mole Percent Composition of Rare Earth-Lithium- 
Borate Glasses Investigated for Use as a Biodegradable 
________________Radiopharmaceutical.________________
X
(r e 2o 3)* y
Glass Series (mole %) (mole %)
HoLB
0.5Ho20 3.yLi20.(100 -  y)B20 3 0.5 4.7-41.0
HoLAB
2Ho2O3.3MgO.5SiO2.yAl2O3.(90 -  y)Li2B80 13 2.0 5-20
YLAB
5Y2O3.3MgO.5SiO2.10Al2O3.77Li2B8O 13 5.0 —
SmLAB
5Sm20 3.3M g0.5S i02.10Al20 3.77Li2B80 13 5.0 —
*RE a  Dy, Ho, Y, or Sm.
Most of the glasses were melted between 1000 and 1150° C. 
The melting temperature of the glasses which contained both 
A120 3 and Si02 was slightly higher at 1200 to 1300° C. 
Each melt was held at its melting temperature for approxi­
mately 30 minutes (up to one hour for the RELAB glasses) 
to assure complete melting and homogeneity. After this 
period, the melts were stirred once with an alumina rod and 
cast into a bar or patty on a stainless steel plate.
The glasses were stored in a desiccator until they were 
annealed for property measurements or crushed for sphe- 
roidization. The batch composition of the rare earth-lithium 
borate glasses are listed in Tables II through V.
TABLE II
Mole and Weight % Composition (wt % in 
______Parenthesis) of DyLB Glasses.______
Glass b 2o 3 Li20 Dy20 3 Li20 /B 20 3 Glass Formation'
DyLB-1 74.37 24.79 0.84 H. Glass
(83.11) (11.89) (5.00) 0.33 (p)
DyLB-2 74.04 24.68 1.28 H. Glass
(80.93) (11.58) (7.49) 0.33 (p)
DyLB-3 73.68 24.57 1.75 H. Glass
(78.73) (11.27) (10.00) 0.33 (p)
DyLB-4 72.90 24.36 2.75 H. Glass
(74.33) (10.66) (15.01) 0.33 (p)
DyLB-5 72.04 24.10 3.85 H. Glass
(69.92) (10.04) (20.04) 0.33 (p)
DyLB-6 85.26 12.84 1.90 H. Glass
(84.46) (5.46) (10.08) 0.15 (p)
DyLB-7 81.76 16.62 1.84 H. Glass
(82.76) (7.24) (10.00) 0.20 (p)
DyLB-8 78.53 19.67 1.80 H. Glass
(81.28) (8.74) (9.98) 0.25 (p)
DyLB-9 70.17 28.12 1.71 H. Glass
(76.77) (16.21) (10.02) 0.40 (p)
DyLB-10 67.82 30.50 1.68 H. Glass
(75.43) (14.56) (10.01) 0.45 (p)
DyLB-11 59.06 39.37 1.57 P. Crystalline
(70.00) (20.03) (9.97) 0.67 (SQ)
DyLB-12 49.26 49.28 1.46 P. Crystalline
(62.96) (27.04) (10.00) 1.00 (SQ)
DyLB-13 39.46 59.20 1.34 P. Crystalline
(54.77) (35.27) (9.96) 1.50 (SQ)
*(P) = Cast on steel plate; (SQ) = Splat quenched between steel plates; H 
= Homogeneous; S = Slightly; P = Partly
TABLE III
Glass
Mole and Weight % Composition (wt % in 
Parenthesis! of HoLB Glasses.
b 2o 3 Li20 Dy20 3 Li20 /B 20 3 Glass Formation*
HoLB-1 94.80 4.70 0.05 H. Glass
(95.25) (2.03) (2.73) 0.05 (p)
HoLB-2 90.50 9.00 0.50 H. Glass
(93.23) (3.98) (2.80) 0.10 (p)
HoLB-3 82.90 16.60 0.50 H. Glass
(89.39) (7.68) (2.93) 0.20 (p)
HoLB-4 76.50 23.00 0.50 H. Glass
(85.87) (11.08) (3.05) 0.30 (SQ)
HoLB-5 73.70 25.80 0.50 S. Crystalline
(84.24) (12.66) (3.10) 0.35 (SQ)
HoLB-6 71.10 28.40 0.50 H. Glass
(82.67) (14.17) (3.16) 0.40 (SQ)
HoLB-7 68.60 30.90 0.50 H. Glass
(81.11) (15.68) (3.21) 0.45 (SQ)
HoLB-8 66.30 33.20 0.50 M. Crystalline
(79.63) (17.11) (3.26) 0.50 (SQ)
HoLB-9 58.50 41.00 0.50 P. Crystalline
(74.23) (22.33) (3.44) 0.70 (SQ)
*(P) = Cast on steel plate; (SQ) = Splat quenched between steel plates; H
= Homogeneous; S = Slightly; P = Partly; M = Mostly
TABLE IV
Mole and Weight % Composition (wt % in Parenthesis) of
DvMLB Glasses.
Li20 /  Glass
Glass b 2o 3 Li20 Dy20 3 MgO B20 3 Formation*
DyMLB-1 73.43 24.22 1.74 1.61 H. Glass
(77.82) (11.17) (10.01) (1.00) 0.33 (P)
DyMLB-2 70.69 23.67 3.83 1.80 H. Glass
(69.02) (9.92) (20.04) (1.02) 0.33 (P)
DyMLB-3 68.92 23.03 3.79 4.26 H. Glass
(67.85) (9.73) (19.99) (2.43) 0.33 (P)
DyMLB-4 65.74 21.96 3.74 8.56 H. Glass
(65.63) (9.41) (20.01) (4.95) 0.33 (P)
DyMLB-5 59.65 19.94 3.63 16.78 H. Glass
(61.26) (8.79) (19.97) (9.98) 0.33 (P)
DyMLB-6 53.96 18.00 3.54 24.50 H. Glass
(56.91) (8.15) (19.98) (14.96) 0.33 (P)
DyMLB-7 70.49 16.65 3.87 8.98 H. Glass
(68.05) (6.90) (20.03) (5.02) 0.24 (P)
DyMLB-8 74.75 17.70 3.94 3.61 H. Glass
(70.84) (7.20) (19.98) (1.98) 0.24 (P)
* H = Homogeneous; (P) = cast on steel plate.
TABLE V
Mole and Weight % Composition (wt % in Parenthesis) of
RELAB Glasses* * IRE = Dv. Ho. Y. or Sml.
Glass
For-
Glass B20 3 Li20  RE20 3 A120 3 MgO S i0 2 mation*
Dy- 66 16 5 5 3 5 H.
LAB-
5
(58.39) (6.08) (23.70) (6.48) (1.54) (3.82) Glass
(p)
Dy- 62 15 5 10 3 5 H.
LAB-
10
(53.48) (5.55) (23.11) (12.63) (1.50) (3.72) Glass
(p)
Dy- 58 14 5 15 3 5 H.
LAB-
15
(48.81) (5.06) (22.55) (18.49) (1.46) (3.63) Glass
(p)
Dy- 54 13 5 20 3 5 H.
LAB-
20
(44.37) (4.58) (22.01) (24.07) (1.43) (3.55) Glass
(p)

















Mole and Weight % Composition (wt % in Parenthesis) of 
______ RELAB Glasses * * (RE = Dy, Ho, Y, or Sm).______
Glass
For-
Glass B20 3 Li20 r e 2o 3 a i2o 3 MgO S i0 2 mation*
LAB-
5
(68.22) (7.33) (10.91) (7.36) (1.75) (4.34) Glass
(p)
Ho- 64 16 2 10 3 5 H.
LAB-
10
(32.49) (6.71) (10.60) (14.30) (1.70) (4.21) Glass
(p)
Ho- 60 15 2 15 3 5 H.
LAB-
15
(56.97) (6.11) (10.31) (20.86) (1.65) (4.10) Glass
(p)
Ho- 56 14 2 20 3 5 H.
LAB-
20
(51.75) (5.55) (10.03) (27.07) (1.61) (3.99) Glass
(p)
Y- 66 16 5 10 3 5 H.
LAB-
10
(58.85) (6.11) (15.39) (13.90) (1.65) (4.10) Glass
(p)
Sm- 62 15 5 10 3 5 H.
LAB-
10
(54.30) (5.64) (21.94) (12.83) (1.52) (3.78) Glass
(p)
*H = Homogeneous; (P) = cast on steel plate.
**Li20 /B 20 3 = 0.24 for all RELAB glasses.
fT he number included in the glass ID corresponds to the mole % A120 3 in 
the glass (For the RELAB glasses only).
(2) Property Measurements
The density of the glasses at 25° C. was measured by 
Archimedes’ buoyancy method using kerosene as the sus­
pension medium whose density (0.8015 g/cm2 at 25° C.) 
was determined using a Gay-Lussac specific gravity bottle. 
For density measurement, the dry and suspended mass of a 
crack-and bubble-free piece of each annealed glass was 
measured on an analytical balance. The experimental error 
in the density was estimated to be ±0.01 g/cm2.
The nD refractive index was measured by the Becke line 
method using certified refractive index liquids and a filter 
which transmitted only sodium D(589 nm) light. Annealed 
glasses that were crushed with a porcelain mortar and pestle 
were used for the refractive index measurement. The error 
for the refractive index was ±0.002.
(3) Chemical Durability Measurement
The chemical durability of the glasses that contained 
Dy20 3 or Ho20 3 was evaluated by measuring the weight 
loss of as-cast or annealed bulk glass samples that were 
immersed in phosphate buffered saline (PBS) solution (pH 
7.4) at 37° C. PBS solution at 37° C. was used as the 
corrosion medium to simulate both the ion content, listed in 
Table VI, and temperature of body fluids, e.g. synovial fluid.
TABLE VI
Molar Content of Inorganic Electrolytes in 
Phosphate Buffered Saline (PBS) Solution Used in Corrosion Testing 
of RELAB Glasses.




H2P 0 47 H P 0 42- 9.6
The as-cast samples for corrosion testing were selected from 
pieces of the DyLB, HoLB, DyMLB, DyLAB or HoLAB 
glasses that were free of cracks or thin, pointed edges.
Rectangular glass samples (plates) for corrosion testing 
were cut from annealed DyMLB and DyLAB glasses and 
polished to a 0.05 fim surface finish using SiC paper and 
A120 3 polishing abrasive. Only non-aqueous lubricants, i.e.
kerosene and mineral oil, were used during the cutting and 
polishing to avoid corrosion of the glass before testing. Any 
residual kerosene or mineral oil was removed from the glass 
surface prior to testing by rinsing the plates with acetone. 
Glass plates (=10x5x2 mm) were used so that the dissolution 
rate (DR in g/cm2/min.) could be calculated from the weight 
loss of the glass. Prior to immersion in the PBS solution, the 
surface area of the DyMLB and DyLAB glass plates was 
estimated from their bulk dimensions, and the initial weight 
of all the glass samples was determined.
The bulk glass samples (as-cast pieces or annealed glass 
plates) were immersed separately in approximately 100 ml 
of PBS solution at 37° C. that was contained in high density 
polyethylene (HDPE) bottles. The glass samples were peri­
odically removed from the PBS solution, gently rinsed with 
acetone to remove any residual PBS, and dried in air at 70° 
C. for at least 30 minutes. After drying, the reacted or 
corroded glass samples were weighed and placed back into 
their respective PBS solution for further testing. These steps 
were repeated several times for up to 18 days (or 75 and 90 
days for the DyLAB and HoLAB glasses respectively).
Inductively coupled plasma spectroscopy (ICP) was used 
to measure the amount of Dy, if any, released from the DyLB 
and DyMLB glass samples after immersion in the PBS 
solution at 37° C. for 5 or 24 hours. Approximately 10 ml of 
the PBS solution from each glass sample was decanted and 
replaced with fresh solution. The decanted PBS solution was 
filtered to remove any particulates and analyzed by ICP to 
determine the Dy concentration. Note that within 5 and 24 
hours, 77.8 and 99.9% of radioactive 165Dy, respectively, 
decays to its non-radioactive daughter, 165Ho.
(4) Glass Microsphere Preparation
The feasibility of preparing glass microsphere for in vivo 
use from rare-earth lithium borate glasses was tested using 
the flame spheroidization technique. Flame spheroidization 
was attempted using at least one of each of the DyLB, 
HoLB, DyMLB, DyLAB and HoLAB glass compositions 
from Table I above. Each glass was crushed with a porcelain 
mortar and pestle and sieved to obtain a -45 fim (-325 
mesh) powder. The glass powder was slowly dropped into a 
propane/air flame, via a vibrating spatula located above the 
flame, where each particle became molten and was drawn 
into a sphere by surface tension. Upon exiting the flame, the 
spherical droplets cooled to a glass and were collected in a 
stainless steel cylinder.
RESULTS
(1) Rare Earth-Lithium Borate Glass Formation
Each rare earth-lithium borate glass batch completely 
melted and become bubble-free after being held at its 
respective melting temperature (1000 to 1300° C.) for a few 
minutes. All of the glass melts were noticeably more fluid 
than molten B20 3 or most glass forming silicate melts. The 
viscosity of a typical soda-lime-silicate glass at its “melting” 
temperature, 1450° C., is 10 to 100 poise. The low viscosity 
of the rare earth-lithium borate glass melts is an advantage 
since it aids homogenization of the melt and decreases the 
time needed for fining which limits any loss of the more 
volatile elements such as boron and lithium. There was no 
evidence of volatilization from the rare earth-lithium borate 
melts, except for slight fuming that was only observed for 
the Dy-LAB-20 melt that was melted at 1300° C.
Most of the DyLB and HoLB and all of the rare earth- 
lithium borate glasses that contained A120 3, MgO and 
and/or S i0 2 (DyMLB, DyLAB, HoLAB, YLAB and 
SmLAB) formed a clear glass when cast on a steel plate, as 
indicated in Tables II through VI. The rare earth-lithium 
borate glasses contained some striae but otherwise appeared 
homogeneous. All of the rare earths, except Y, resulted in 

















(2) Density and Refractive Index
The density of the rare earth-lithium borate glasses ranged 
from 2.29 to 2.95 g/cm3 and increased linearly with increas­
ing mole % Re20 3.
The refractive index (n ,^) of the rare earth-lithium borate 
glasses ranged from 1.544 to 1.604 and increased with 
increasing mole % rare earth oxide, which was expected 
from the increase in density. However, fluctuations in the 
refractive index due to the addition of A120 3 or MgO were 
more pronounced than those for the density of the rare 
earth-lithium borate glasses.
(3) Chemical Durability to the Rare Earth-Lithium Borate 
Glasses
The chemical durability of a rare earth-lithium borate 
glass is important from the standpoint of both unwanted 
radiation leakage and eventual disintegration and dissolution 
of the glass. The rare earth-lithium borate glass micro­
spheres should preferably completely retain the rare earth 
radionuclide within the treatment site while it is still sig­
nificantly radioactive, which is approximately one, 11 , 20 or 
27 days (i.e. 10 half-lives) for 1(” Dy, 166Ho, 90Y, or 153Sm, 
respectively. Ten half-lives correspond to the time when 
99.9% of the radiation has decayed, at which point the rare 
earth-lithium borate glass microspheres could completely 
disintegrate without releasing harmful amounts of radiation.
(a) Release of Dy
No detectable amount of Dy (=0.1 ppm) was found by 
ICP analysis in any of the PBS solutions that were in 
contact with the DyLB (1 through 5) or DyMLB 
glasses for 5 to 24 hours at 37° C. These results were 
confirmed by testing two additional samples of each 
DyMLB glass.
(b) Weight Loss and Dissolution Rate
The chemical durability of the rare earth-lithium borate 
glasses varied drastically with composition, and gen­
erally increased with increasing mole % rare earth 
oxide. The weight loss and dissolution rate (DR) for the 
DyLB and DyMLB glasses after 8 days and the 
DyLAB and HoLAB glasses after 7 days are listed in 
Tables VII and VIII, respectively.
Overall, the HoLB and DyLB glasses were the least 
durable rare earth-lithium borate glasses. The DyLB-1 
through DyLB-5 glasses, which contained from 0.84 to 3.9 
mole % Dy20 3, respectively, were more durable than the 
HoLB glasses and did not fully react within 24 hours. As a 
whole, the DyMLB glasses were slightly more durable than 
the DyLB glasses and had from 1.0 to 13.7% weight loss 




Percent Weight Loss and Dissolution Rate for 
DyLB, DyALB, and DyMLB Glasses (Mole % D y2Os and A120 3 or 





A120 3 or MgO
% Weight Loss
±0 .2%*
DR±23 x 10-8 
(g/cm2/min.)*
DyLB-1 0.84 0 24.5 nm
DyLB-2 1.28 0 21.8 nm
DyLB-3 1.75 0 14.3 nm
DyLB-4 2.75 0 7.9 nm
DyLB-5 3.85 0 2.5 nm
DyMLB-1 1.77 1.61 7.9 nm
DyMLB-2 3.83 1.80 3.3 nm
DyMLB-3 3.79 4.26 5.4 nm
DyMLB-4 3.74 8.56 8.1 89
DyMLB-5 3.63 16.78 4.4 63
DyMLB-6 3.54 24.50 4.8 90
TABLE VH-continued
Percent Weight Loss and Dissolution Rate for 
DyLB, DyALB, and DyMLB Glasses (Mole % Dy2Os and A l2Os or 
________________ MgO are included for Comparison.________________
Mole % Mole % % Weight Loss DR±23 x K T8
Glass Dy20 3 Al2Os or MgO ±0.2%* (g/cm2/min.)*
DyMLB-7 3.87 8.98 1.0 20
DyMLB-8 3.94 3.61 2.4 73
*After =8 days (200 hours) in PBS solution at 37° C.
(nm) not measured
TABLE VIII
Percent Weight Loss and Dissolution Rate for 









DR± 0.1 x 10~8 
(g/cm2/min.)*
DyLAB-5 5.0 5 2.740 173.3
DyLAB-10 5.0 10 0.040 2.7
DyLAB-15 5.0 15 0.003 0.1§
DyLAB-20 5.0 20 (nd) (nd)
HoLAB-10 2.0 10 4.866 461.0
HoLAB-15 2.0 15 0.822 21.2
HoLAB-20 2.0 20 (nd) (nd)
YLAB-10 5 10 nm nm
SmLAB-10 5 10 nm nm
f  RE = Dy, Ho, Y  or Sm
(nm) not measured.
*After =7 days in PBS solution 37° C.
^Measured weight loss was within the calculated experimental error.
(nd) No detectable weight loss (±0.05 mg uncertainty).
The DR of the DyMLB glasses (listed in Table VII) was 
the same order of magnitude (10-2 g/cm2 min.) for all the 
glasses but, like the percent weight loss, was somewhat 
inconsistent with differences in composition.
The DyLAB glasses were generally much more chemi­
cally durable than the DyLB or DyMLB glasses, which was 
not surprising since the DyLAB glasses had the highest 
Dy20 3 content (5 mole %) and contained Si02, A120 3 and 
MgO. The HoLAB glasses contained less rare earth (2 mole 
% Ho20 3) than the DyLAB glasses and were, consequently, 
less chemically durable. The DyLAB-15, DyLAB-20 and 
HoLAB-20 glasses, which lost little or no weight in the PBS 
solution at 37° C. are clearly the least degradable of the rare 
earth-lithium borate glasses.
(4) Rare Earth-Lithium Borate Glass Microsphere Pabrica- 
tion
Solid glass microspheres (1 to 40 fim in diameter) were 
successfully prepared from all of the DyLAB and HoLAB 
glasses and the DyLB-3, DyLB-8, DyMLB-6, DyMLB-8 
and HoLB-5 glasses. The microspheres made from the 
DyLAB-5 glass exhibited uniformity and smooth surfaces 
representative of all the rare earth-lithium borate micro­
spheres prepared by flame spheroidization. A small fraction 
of the rare earth-lithium borate glass microspheres contained 
one or more small gas bubbles which should not have any 




Pifty grams of each of the dysprosium and holmium 
glasses listed in the following Table IX were prepared by 
melting a homogeneous mixture of high purity powders (i.e. 
Dy20 3, H3B 03, Li2C 03, A120 3, Si02 and Mgo) in a plati­


















Mole % Composition of the DyLAB and HoLAB Glasses 
Investiaated for In Vivo Radiotherapy.
Glass* r e 2o 3** Li20 a i2o 3 b 2o 3 S i0 2 Mgo
DyLAB-5 5(23.7) 16 5 66 5 3
DyLAB-10 5(23.1) 15 10 62 5 3
DyLAB-15 5(22.6) 14 15 58 5 3
DyLAB-20 5(22.0) 13 20 54 5 3
HoLAB-10 2(10.6) 16 10 64 5 3
HoLAB-15 2(10.3) 15 15 60 5 3
Ho LAB-20 2(10.0) 14 20 56 5 3
*The number in each Glass ID corresponds to the mole % A120 3 in the 
glass.
**Dy20 3 (DyLAB) or Ho20 3 (HoLAB). Weight % in parenthesis.
All batch materials used to prepare the glasses were oxides 
except H3BO3 and Li2C 03. Each batch melted completely 
and was mostly bubble free between 1200 and 1300° C. after 
less than 30 minutes. The viscosity of the melts was much 
lower than that of soda-lime glass (10 to 100 Poise at -1500° 
C.). Each melt was held at its melting temperature for 
approximately one hour before being stirred with an alumina 
rod and then cast into a bar or patty on a stainless steel plate. 
A portion of each dysprosium glass was annealed in air at 
500° C. for 30 minutes. The annealed dysprosium glasses 
were inspected for any residual stress by viewing them 
through cross polarized light.
(2) Glass Microsphere Formation
For glass microsphere formation, the glasses were 
crushed with a porcelain mortar and pestle and the particles 
were sieved to obtain a -45 fim (-325 mesh) glass powder. 
The glass powder was then fed to a propane/air flame where 
each particle melted and spheroidized due to surface tension. 
Upon exiting the flame, the spherical particles cooled to 
solid glass microspheres and were collected in a large 
stainless steel cylinder (barrel). Microspheres were prepared 
from each glass listed in Table IX above. After 
spheroidization, the glass microspheres were dry sieved to 
size ranges of +38, -38/+32, -32/+25, -25/+20, and -20 fim 
in diameter and then stored in a desiccator.
(3) Chemical Durability Measurements
(A) Weight Loss.
For corrosion testing of bulk dysprosium and holmium 
glasses, rectangular samples (plates) were cut from the 
annealed dysprosium glasses, and an as-cast piece of 
each holmium glass was selected. The dysprosium 
glass plates were polished to a 0.05 fim finish using SiC 
paper and A120 3 polishing abrasive. Only non-aqueous 
lubricants were used during cutting and polishing to 
minimize potential corrosion of the glass before testing. 
The lubricants were removed from the glass surface by 
washing the samples in acetone. The weight and sur­
face area of the bulk dysprosium and holmium glass 
samples were measured prior to corrosion testing. 
Since the holmium glass samples were not rectangular, 
their surface area was only an estimate.
The bulk dysprosium and holmium glass samples were 
corroded separately using phosphate buffered saline 
(PBS) solution (pH 7.4) at 37° C. in high density 
polyethylene bottles. The PBS solution (Sigma Chemi­
cal Co., St. Louis, Mo.) was used since its pH and 
inorganic ion content is very close to that of fluids in 
the body. The glass surface area to solution volume 
(SA/V) ratio for each glass sample was approximately
0.1 cm-1. Periodically, the glass samples were removed 
from the PBS solution, briefly submerged in acetone to 
remove any residual PBS, and dried in air at 70° C. for
30 minutes. The glass samples were then weighed and 
immediately replaced in their respective PBS solution 
for further testing. These steps were repeated several 
times for up to 90 days. The dissolution rate (DR in 
g/cm2/min.) of each dysprosium and holmium glass for 
a given period was determined by dividing the weight 
loss by the initial surface area and elapsed dissolution 
time.
(B) Solution Analysis.
Inductively coupled plasma spectroscopy (ICP) or scin­
tillation counting of leached radioactive 165Dy were 
used in two separate experiments to quantify the 
amount of Dy3+, if any, that dissolved from the above- 
noted DyLAB glass microspheres during corrosion. For 
ICP analysis, approximately 70 mg of non-radioactive 
DyLAB-5, DyLAB-10, DyLAB-15 or DyLAB-20 
glass microspheres (28±4 fim average diameter) were 
corroded in 30 ml of PBS solution at 37° C. (estimated 
SAW-1.8 cm-1) for 5 or 24 hours. In one case, ICP was 
used to analyze the PBS solution that had been in 
contact with DyLAB-10 glass microspheres for 23 
days. After submersion for 5 or 24 hours (or 23 days), 
the glass microspheres were vacuum filtered from the 
PBS solution and examined by scanning electron 
microscopy (SEM). Each PBS solution was analyzed 
by ICP to determine the amount of Dy and other glass 
components, i.e. B, Al, Si and Mg, in solution. The ICP 
equipment used had a lower detection limit of 0.1 ppm 
for Dy, B, Al, Si and Mg.
The radioactivity of deionized (DI) H20  in which neutron 
activated DyLAB-10 or DyLAB-20 glass microspheres 
were immersed at 37° C. (estimated SA/V~cm-1) was 
measured to determine the amount of radioactive 165Dy 
in solution. Approximately every three hours, V2 of each 
test solution was removed and replaced with an equal 
volume of fresh DI H20. The decanted test solution 
was filtered to eliminate any glass microspheres and 
then analyzed by counting the 94 KeV gamma emis­
sions of 165Dy. The radioactivity of the DyLAB glass 
microspheres was also measured as a control.
(C) Surface Analysis.
Electron dispersion spectroscopy (EDS) and x-ray pho­
toelectron spectroscopy (XPS) were used to determine 
the surface composition of as-made and corroded 
DyLAB glass plates. Of most interest was the concen­
tration of Dy in the corroded surface of the DyLAB 
glasses as compared to the as-made glass. EDS analysis 
was performed on the same DyLAB-5 glass plate that 
had been corroded for the weight less measurement. 
For XPS analysis, a separate set of DyLAB-10 glass 
plates were corroded in PBS solution at 37° C. for 0, 5, 
24 or 336 hours (2 weeks).
(D) In-Vivo Testing of Glass Microspheres.
A preliminary investigation of the in vivo chemical dura­
bility and biocompatibility of the glass microspheres 
was made by injecting non-radioactive DyLAB-10 
glass microspheres directly into the healthy stifle joint 
(knee) of a rat. The DyLAB-10 glass microspheres (20 
to 25 fim in diameter) were suspended in a 75 wt. % 
glycerol-saline solution (0.04 mg of spheres/wl) prior to 
injection. The glycerol was used to increase the vis­
cosity of the carrier liquid so that the glass micro­
spheres remained suspended for injection. Fifty and 
100 fi\ of the above suspension, i.e. 2 and 4 mg of 
DyLAB-10 glass microspheres (roughly 50,000 

















The animal was sacrificed two weeks after injection of the 
glass microspheres and thin tissue sections were pre­
pared from each stifle joint. For preparation of the 
tissue sections, the joints were removed from the rat, 
dehydrated, and fixed in polymethylmethacrylate. Thin 
sections were cut from the fixed joints, along the 
sagittal plane, and polished using SiC paper and A120 3 
polishing abrasive. The polished sections were exam­
ined by optical microscopy to determine the physical 
condition of the DyLAB-10 glass microspheres and the 
surrounding synovial tissue and any evidence of tissue 
necrosis or other adverse responses.
RESULTS
(1) Rare Earth Glass Formation
All of the dysprosium and holmium melts cooled to a 
clear glass that was free of bubbles and unmelted batch 
material. The dysprosium and holmium glasses were yellow 
or orange in color, respectively, and contained some striae, 
but were otherwise homogeneous in appearance. Residual 
stress in the dysprosium glasses was adequately removed by 
annealing the glasses at 500° C. in air for 30 minutes.
Microspheres were successfully produced from each of 
the dysprosium and holmium glasses, and all were alike in 
both their formation qualities and appearance. The repre­
sentative photomicrograph in FIG. 2 shows the uniformity 
and smooth surface texture of the glass microspheres that 
were prepared by flame spheroidization. Although not vis­
ible in FIG. 2, a small fraction of the glass microspheres 
contained one or more gas bubbles.
(2) Dissolution Rate of Dysprosium and Flolmium Glasses
The cumulative percent weight loss per surface area
(%WL/cm2) of the bulk dysprosium (5 mole % Dy20 3) and 
holmium (2 mole % Flo20 3) glass samples after immersion 
in PBS solution at 37° C. for 1, 7 or 75 days (90 days for 
holmium glasses is listed below in Table X.
TABLE X
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Percent Weight Loss Per Surface Area for DyLAB and 
HoLAB Glasses Corroded in PBS Solution at 37° C. (SA/V = 0 .1  cm "1).
Glass
ID % WL/cm2 ± 0.001
24 h 7 d 75 d
DyLAB-5 0.035 0.258 1.163
DyLAB-10 0.007 0.009 0.166
DyLAB-15 4=4= O.OOlf 4=4=
DyLAB-20 4=4= 4=4= 4=4=
24 h§ 7 d§ 90 d§
HoLAB-10 4=4= 4.443 33.532
HoLAB-15 4=4= 0.204 2.200
HoLAB-20 4=4= 4=4= 0.189
** -No detectable weight loss (±0.05 mg uncertainty). 
f-M easured weight loss within calculated experimental error.
§-Calculated from estimated surface area.
The weight loss results show that the chemical durability of 
the glasses varied significantly, increasing with increasing 
A120 3 (5 to 20 mole %). For instance, the DyLAB-5 and 
DyLAB-10 glass plates (5 and 10 mole % A120 3, 
respectively) had a total weight loss of 1.16 and 0.17%/cm2 
after 75 days, respectively, whereas the DyLAB-15 and 
DyLAB-20 glass plates (15 and 20 mole % A120 3, 
respectively) had little to no measurable weight loss. 
Likewise, the weight loss of the FloLAB glass plates after 90 
days decreased from 33.53 to 0.19%/cm2 as the A120 3 
content increased from 10 to 20 mole %.
The DyLAB glasses were clearly more chemically 
durable than the FloLAB glasses that contained equal mole
% A120 3, which is attributed to the difference in the amount 
(5 or 2 mole % Dy20 3 or Flo20 3, respectively) rather than 
to the specific rare earth oxide. The mole % Dy20 3 or Flo20 3 
was held constant within each RELAB glass series, DyLAB 
or FloLAB, in order to standardize the neutron activation 
time and the resulting specific activity of the RELAB glass 
microspheres. The chemical durability of the DyLAB and 
FloLAB glasses was controlled by adjusting the A120 3 
content which would have no effect on the neutron activation 
time.
(3) Release of Dysprosium from DyLAB Glass Micro­
spheres
No measurable amount of radioactivity (sub-nCi detec­
tion limit) was released from neutron activated DyLAB-10 
or DyLAB-20 glass microspheres immersed in deionized 
water at 37° C. for up to 11 hours (i.e. 4.8 half-lives for 
165Dy during which 96.4% of the radiation decays). The 
absence of any detectable radiation in the deionized water is 
important evidence that no radiation would be released 
outside the treatment site and supports the safety of using 
DyLAB glass microspheres in vivo. Furthermore, these 
results demonstrate that neutron activation does not 
adversely affect the chemical durability of the DyLAB glass 
microspheres. The lack of Dy release from the radioactive 
DyLAB glass microspheres was confirmed by similar mea­
surements using nonradioactive microspheres.
The ICP analysis of the PBS solution that was in contact 
with the DyLAB glass microspheres at 37° C. indicates that 
the weight loss of the glass was due to dissolution of the 
non-activatable glass components and not to the dissolution 
of Dy. No measurable amount of Dy (>0.1 ppm) was 
detected by ICP analysis of the PBS solution that had been 
in contact with DyLAB-5, DyLAB-10, DyLAB-15 or 
DyLAB-20 glass microspheres at 37° C. for up to 24 hours. 
This is significant since in 24 hours, 99.9% of the 165Dy 
decays to its non-radioactive daughter isotope 165F1o. In 
other words, no detectable amount of radioactive 165Dy 
would be released in the first 24 hours. Dysprosium was 
likewise not detected in the PBS solution that contained 
DyLAB-10 glass microspheres for 23 days.
Although there was no evidence that any Dy was dis­
solved from the DyLAB glass microspheres, detectable 
amounts of B, Al, Si and Mg were dissolved from the 
microspheres of each DyLAB glass. The amount of specific 
glass components that dissolved from the DyLAB glass 
microspheres decreased with increasing mole % A120 3 in 
the glass, i.e. the overall corrosion resistance of the DyLAB 
glass microspheres increased with increasing A120 3 content, 
which was also true for the bulk DyLAB glass plates (see 
Table X).
As has been shown, the RELAB glasses do not dissolve 
uniformly and none of the radioactive rare earth, including 
166F1o, 90Y or 153Sm, would be expected to be released from 
RELAB glass microspheres. Non-uniform dissolution of the 
RELAB glass microspheres where the rare earth radionu­
clide is retained in the glass is clearly an advantage for safe 
in vivo radiotherepy, especially for glasses that contain the 
longer-lived 166Ho, 90Y or 153Sm.
(4) Formation of a Dy Rich Reaction Layer
Several techniques were used to verify the formation of a 
Dy rich reaction layer on the surface of the DyLAB glass 
plates and microspheres that were immersed in PBS at 37° 
C.
(A) SEM and Optical Microscopy
SEM and optical microscopy show that a visible reaction 
layer formed on both the microspheres and plates of 
DyLAB-5 and DyLAB-10 glass that were immersed in 
PBS solution. SEM photomicrographs of the DyLAB-5 
and DyLAB-10 glass microspheres after 24 hours in 
















partial separation of a layer from the microsphere 
surface. The cracks on the surface of the DyLAB glass 
microspheres appeared when the spheres were dried, 
which suggest capillary stress gradients and shrinkage 
that are characteristic of dehydration. This indicates 
that the corroded surface of the DyLAB-5 or DyLAB- 
10 glass was permeable to the PBS solution and 
mechanically weaker than the starting glass, probably 
due to a more open structure and porosity resulting 
from corrosion.
(B) EDS Analysis
Cracks were also seen on the surface of the DyLAB-5 and 
DyLAB-10 glass plates, pictured in FIGS. 4(a) and (b). 
FIG. 4a also shows that a fraction of the corrosion layer 
on the DyLAB-5 glass plate was separated from the 
glass that had been immersed in PBS at 37° C. for 11 
days. From ICP analysis of the solution, it was not 
surprising that the atomic ratio of Dy to A1 plus Si 
(Dy/Al+Si)), as determined by EDS, was 3.3 times 
greater in the corrosion layer that separated from the 
DyLAB-5 glass than in the as-made DyLAB-5 glass. 
Since no detectable amount of Dy leached from the 
DyLAB glasses, the concentration of Dy in the cor­
roded glass was expected to increase as the other glass 
components dissolve in either PBS solution or deion­
ized water. EDS analysis also revealed that Mg, a 
component of the DyLAB glasses, was absent from the 
corroded layer on the DyLAB-5 glass.
(C) XPS Analysis
The surface resolution of XPS analysis of glass is 10 to 20 
A, compared to approximately one micron for EDS, 
and can be combined with ion sputter milling to give a 
compositional depth profile. The increasing size of the 
peak caused by Dy in the XPS spectra (not shown) 
indicates that the concentration of Dy in the DyLAB-10 
glass increased as corrosion progressed. Based on the 
size of the XPS peaks for B and Al, the concentration 
of B and Al appears lower to a depth of 1000 and 80 A, 
respectively, in the DyLAB-10 glass immersed for 5 or 
24 hours. The XPS peaks for B and Al in the 2 week 
DyLAB-10 glass sample most closely resemble those 
of as-made DyLAB-10 glass plate. The Dy concentra­
tion appears to remain the same or to increase in the 
DyLAB-10 glass even after 2 weeks of corrosion, 
rather than decrease as it would if Dy was being 
dissolved from the glass.
XPS analysis also revealed that phosphorus ions from the 
PBS solution were present in the surface of the 
DyLAB-10 glass after immersion for 5, 24 or 336 
hours. The XPS spectra for the samples immersed for 
5 or 24 hours show that the concentration of phospho­
rus decreased with depth but increased with dissolution 
time. This concentration gradient suggests that phos­
phorus was diffusing into the corrosion layer and 
possibly reacting with the undissolved glass compo­
nents rather than simply precipitating on the surface.
(D) Real Time Video Microscopy (RTVM)
Reaction of the DyLAB glass microspheres is most viv­
idly shown by real time video microscopy (RTVM). 
RTVM clearly demonstrates that the size of the DyLAB 
glass microspheres does not decrease when the micro­
spheres begin to degrade in the PBS solution. The 
chronological RTVM images in FIG. 5 of the DyLAB- 
10 glass microspheres in PBS solution (estimated 
SA/V<0.1 cm-1) at 22° C. illustrate the growth of a 
layer that starts at the outer surface of the microsphere 
and grows inward with increasing time. This “shell”
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was first noticed after approximately 5 and 26 hours for 
the DyLAB-5 and DyLAB-10 glass microspheres, 
respectively, and is visual proof that a reaction layer 
was formed on the glass. The images in FIG. 5 show 
that the outer diameter (reaction layer/solution 
interface) of the DyLAB-10 glass microspheres 
remained nearly constant and the reaction layer grew 
thicker as the glass/corrosion layer interface moved 
toward the center of each sphere. This gave the appear­
ance of a shrinking, spherical “core” within the DyLAB 
glass microspheres, which is believed to consist of the 
unreacted glass. The fact that the outer diameter of the 
DyLAB glass microspheres did not change is a further 
indication that the corrosion layer mostly consisted of 
undissolved glass components rather than reprecipi­
tated compounds.
(5) In Vivo Corrosion of DyLAB Glass Microspheres
A corrosion layer also formed on the surface of non- 
radioactive DyLAB-10 glass microspheres (23 fim in aver­
age diameter) that were injected into the healthy stifle joint 
(knee) of a rat. Photomicrographs of the DyLAB-10 glass 
microspheres imbedded in the synovial membrane, FIGS. 
6(a) and (b) (two weeks after injection), show evidence of 
a corrosion layer, which is similar in appearance to the 
corroded layer seen on the DyLAB-5 or DyLAB-10 glass 
microspheres immersed in PBS solution at 22 or 37° C. 
Likewise, the size of the DyLAB-10 glass microspheres 
injected into the rat did not decrease noticeably during two 
weeks in the stifle joint. None of the microspheres were 
found outside the synovial membrane (see FIG. 6(A)). There 
was no discernable difference in the stifle joints injected with 
either 2 or 4 mg of DyLAB-10 glass microspheres.
These results indicate that the corrosion testing in simu­
lated body conditions is representative of the behavior of 
ReLAB glass microspheres during in vivo use. There is little 
reason to believe that the corrosion layer on the surface of 
the DyLAB-10 glass microspheres injected into the rat was 
appreciably different in composition than that which formed 
on the surface of the DyLAB-5 or DyLAB-10 glass micro­
spheres immersed in deionized water or PBS solution. Thus, 
the corrosion layer that forms on DyLAB glass microspheres 
imbedded in the synovial membrane would be expected to 
retain most, if not all, of the Dy from the starting glass for 
at least two weeks after the spheres are injected, at which 
time all of the microspheres are non-radioactive. This sug­
gests that none of the injected radioactivity from DyLAB or 
HoLAB glass microspheres would escape, either in the form 
of glass particulates or dissolved 165Dy or 166Ho, outside a 
human joint during radiation synovectomy.
Equally important is the fact that none of the injected 
DyLAB-10 glass microspheres (=100,000 or 200,000 
spheres/joint) were found outside the synovial sac. All of the 
DyLAB-10 glass microspheres appeared to be imbedded in 
the synovial membrane. This is a critical observation since 
ReLAB glass microspheres can deliver a more uniform dose 
of therapeutic radiation when located inside the synovial 
membrane.
The rat resumed normal activity immediately after the 
glass microspheres were injected and did not show any 
negative response during the two weeks the microspheres 
were in the stifle joints. There was no evidence of necrosis 
of the joint tissue or physical damage to the articular 
cartilage, shown in FIG. 6(a), one of the five criteria for in 
vivo use of the RELAB glasses. A foreign body response 
was observed, and the DyLAB-10 glass microspheres were 
engulfed by macrophages (phagocytes) which appear as an 
elliptical halo surrounding the microspheres. The macroph­
ages are visible in FIGS. 6(a) and (b), but are most clearly 
shown surrounding the DyLAB-10 glass microspheres pic­

















response observed in the rat caused any harm to the joint, 
and engulfment of the RELAB glass microspheres by mac­
rophages may be beneficial, since it is considered one 
method whereby the glass microspheres can be removed 
from the body when they are no longer radioactive.
In view of the above, it will be seen that the several 
objects of the invention are achieved and other advantageous 
results attained.
As various changes could be made in the above compo­
sitions and methods without departing from the scope of the 
invention, it is intended that all matter contained in the 
above description or shown in the accompanying drawings 
shall be interpreted as illustrative and not in a limiting sense.
What is claimed is:
1. A nonradioactive glass in particulate form adapted for 
radiation therapy in a mammal comprising a biodegradable 
rare earth-lithium borate glass material having a composi­
tion selected from the group consisting of:




xRE20 3.3M g0.5S i02.yAl20 3.(92-y-x)Li2B80 13
wherein RE is a neutron activatable rare earth element 
which, upon being subjected to an effective amount of 
neutron irradiation, will produce a beta or gamma emitting 
radioisotope, said radioisotope being distributed throughout 
said glass material, x is the mole percent of RE20 3 and 
ranges between approximately 0.5 and 5 and y is the mole 
percent of Li20 , MgO or A120 3 and the balance is a lithium 
borate material glass; wherein said lithium borate glass is 
substantially free of lithium-6 and boron-10; and wherein 
said glass upon being introduced into a body fluid for 
radiation therapy is adapted to react therewith causing said 
radioisotope to form an insoluble compound on the surface 
of said glass material which is retained in said glass material 
and thereby prevented from escaping from the treatment site.
2. A nonradioactive glass as set forth in claim 1 wherein 
said beta or gamma emitting radioisotope is selected from 
the group consisting of dysprosium-165, holmium-166, 
yttrium-90, rhenium-186, rhenium-188 and samarium-153.
3. A nonradioactive glass as set forth in claim 1 wherein 
said rare earth-lithium borate glass material has the follow­
ing composition:
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Dy20 3 1.7 mole %
Li20 24.6 mole %
b 2o 3 73.7 mole %.
4. A nonradioactive glass as set forth in claim 1 wherein
said rare earth-lithium borate glass material has the follow-
ing composition:
Dy20 3 5 mole %
Li20 16 mole %
a i2o 3 5 mole %
b 2o 3 66 mole %
s io 2 5 mole %
MgO 3 mole %.
5. A nonradioactive glass as set forth in claim 1 wherein
said rare earth-lithium borate glass material has the follow-
ing composition:
Dy2o 3 5 mole %
Li20 15 mole %
a i2o 3 10 mole %
b 2o 3 62 mole %
S i0 2 5 mole %
MgO 3 mole %.
6. A nonradioactive glass as set forth in claim 1 wherein 
said glass is adapted for radiation synovectomy of arthritic 
joints in a mammal and said glass is introduced into synovial 
fluid for radiation synovectomy.
7. A nonradioactive glass as set forth in claim 1 wherein 
said glass is spherical in shape.
8. A nonradioactive glass as set forth in claim 7 wherein 
said glass is in the form of microspheres having a diameter 
less than approximately 100 microns.
9. A nonradioactive glass as set forth in claim 8 wherein 
said microspheres have a diameter between approximately 1 
and 40 microns.
10. A nonradioactive glass as set forth in claim 1 wherein 
said insoluble compound formed by said radioisotope is a 
rare earth oxide.
11. A nonradioactive glass as set forth in claim 1 wherein 
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